

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Legorreta Pablo G.</u> (Last) (First) (Middle) C/O ROYALTY PHARMA PLC 110 E. 59TH STREET (Street) NEW YORK NY 10022 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/15/2020	3. Issuer Name and Ticker or Trading Symbol <u>Royalty Pharma plc [RPRX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) CEO, Chairman of the Board	5. If Amendment, Date of Original Filed (Month/Day/Year) 06/15/2020
6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person			

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
LP interests in RPI US Partners 2019, LP	(1)	(1)	Class A Ordinary Shares, par value \$0.0001 per share	1,584,810 ⁽²⁾	0	I	By Spouse
LP interests in RPI US Partners 2019, LP	(1)	(1)	Class A Ordinary Shares, par value \$0.0001 per share	8,802,380 ⁽³⁾	0	I	By Legorreta Investments LLC
ICAI Interests	(4)	(4)	LP interests in RPI US Partners 2019, LP ⁽¹⁾	1,719,074 ⁽³⁾	0	I	By Legorreta Investments LLC

Explanation of Responses:

- Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share, par value \$0.0001 per share ("Class A Ordinary Share") of the Issuer for no additional value.
- These RPI US LP Interests held by the Reporting Person's Spouse were omitted from the Reporting Person's original Form 3 filing due to an inadvertent administrative error.
- This amendment to Form 3 is being filed to correct the terms and the number of RPI US LP Interests and ICAI Interests that was incorrectly reported on the Reporting Person's original Form 3 due to an inadvertent administrative error.
- These ICAI Interests represent a grant of up to 1,719,074 RPI US LP Interests and expire on December 15, 2023. The full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of \$32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at \$20.51 per share to 100% at \$32.30 per share.

/s/ Jason Mehar, as
Attorney-in-Fact, for Pablo 04/15/2022
G. Legorreta

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.